Quest Diagnostics (DGX) Q1 FY2024 earnings: revenue $2.4 billion, up 1.5% on the year
Quest Diagnostics Inc. (DGX) reported revenue of $2.4 billion for Q1 FY2024, the quarter ended 31 March 2024, up 1.5% on the same quarter a year earlier. Net income was $194 million, down 4.0% on the year, and diluted earnings per share $1.72. The figures are the company's own, from the 10-Q it filed with the SEC on 24 April 2024.
Revenue
$2.4 billion
+1.5% on the year · +3.4% on the quarter
Q2 FY2022Q1 FY2024
Operating margin
12.7%
13.1% a year earlier
Q2 FY2022Q1 FY2024
Net income
$194 million
-4.0% on the year · +1.0% on the quarter
Q2 FY2022Q1 FY2024
Diluted EPS
$1.72
-3.4% on the year · +1.2% on the quarter
Q2 FY2022Q1 FY2024
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q1 FY2024
Q4 FY2023
Q1 FY2023
On the quarter
On the year
Last 8 quarters
Revenue
2,366
2,288
2,331
+3.4%
+1.5%
Cost of revenue
1,595
1,552
1,560
+2.8%
+2.2%
Gross profit
771
736
771
+4.8%
0.0%
Gross margin
32.6%
32.2%
33.1%
Selling, general and administrative
440
407
439
+8.1%
+0.2%
Operating income
300
267
305
+12.4%
-1.6%
Operating margin
12.7%
11.7%
13.1%
Interest expense
49.0
46.0
37.0
+6.5%
+32.4%
Pre-tax income
266
237
277
+12.2%
-4.0%
Income tax
66.0
40.0
65.0
+65.0%
+1.5%
Effective tax rate
24.8%
16.9%
23.5%
Net income
194
192
202
+1.0%
-4.0%
Net margin
8.2%
8.4%
8.7%
Diluted EPS
$1.72
$1.70
$1.78
+1.2%
-3.4%
$ million except per share. Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q1 FY2024
Q4 FY2023
Q1 FY2023
On the quarter
On the year
Last 8 quarters
Operating cash flow
154
527
94.0
-70.8%
+63.8%
Capital expenditure
104
72.0
127
+44.4%
-18.1%
Free cash flow
50.0
455
-33.0
-89.0%
Free cash flow margin
2.1%
19.9%
-1.4%
Cash from investing
-213
-114
-158
Cash from financing
-153
130
-76.0
Depreciation and amortisation
116
109
107
+6.4%
+8.4%
Share-based compensation
22.0
19.0
24.0
+15.8%
-8.3%
Buybacks
n/a
275
0.0
Dividends paid
79.0
80.0
74.0
-1.2%
+6.8%
Dividend per share
$0.75
$0.71
$0.71
+5.6%
+5.6%
Diluted shares, weighted
112m
113m
113m
-0.9%
-0.9%
Shares outstanding at period end
111m
111m
112m
+0.3%
-0.8%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q1 FY2024
Q4 FY2023
Q1 FY2023
On the quarter
On the year
Last 8 quarters
Shareholders' equity
6,432
6,307
6,050
+2.0%
+6.3%
Non-controlling interest
37.0
35.0
38.0
+5.7%
-2.6%
Redeemable equity
77.0
76.0
77.0
+1.3%
0.0%
Debt
4,710
4,713
3,975
-0.1%
+18.5%
Operating lease liabilities
489
503
490
-2.8%
-0.2%
Finance lease liabilities
n/a
6.0
n/a
Other liabilities
2,209
2,382
2,164
-7.3%
+2.1%
Total liabilities and equity
13,954
14,022
12,794
-0.5%
+9.1%
Fixed assets
1,810
1,816
1,795
-0.3%
+0.8%
Goodwill
7,830
7,733
7,241
+1.3%
+8.1%
Intangible assets
1,192
1,166
1,077
+2.2%
+10.7%
Securities held for sale or to maturity
n/a
2.0
n/a
Cash and equivalents
474
686
175
-30.9%
+170.9%
Receivables
1,322
1,210
1,254
+9.3%
+5.4%
Inventory
181
190
190
-4.7%
-4.7%
Other assets
1,145
1,219
1,062
-6.1%
+7.8%
Total assets
13,954
14,022
12,794
-0.5%
+9.1%
Questions
What was Quest Diagnostics' revenue in Q1 FY2024?
Quest Diagnostics (DGX) reported revenue of $2.4 billion for Q1 FY2024, the quarter ended 31 March 2024, up 1.5% on the same quarter a year earlier.
How much did Quest Diagnostics earn in Q1 FY2024?
Net income for Q1 FY2024 was $194 million, down 4.0% on the year, and diluted earnings per share $1.72.
When did Quest Diagnostics report Q1 FY2024 results?
Quest Diagnostics filed its 10-Q for the quarter ended 31 March 2024 with the SEC on 24 April 2024.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 31 March 2024, filed 24 April 2024: the filing.